Results 61 to 70 of about 83,328 (323)

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma

Journal for ImmunoTherapy of Cancer, 2020
Background A synergy between radiotherapy and anti-cytotoxic-T-lymphocyte-associated antigen 4 (anti-CTLA-4) monoclonal antibody has been demonstrated preclinically.
Caroline Robert, Christine Mateus, Christophe Massard, Roger Sun, Eric Deutsch, Lydie Cassard, Rastilav Bahleda, Severine Roy, Emilie Routier, Nathalie Chaput-Gras, Caroline Caramella, Emilie Lanoy, Alicia Larive, Yun Gan Tao, Dominique Schwob, Nathalie Ibrahim, Rita Maria Khoury Abboud, J -C Soria   +17 more
doaj   +1 more source

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. [PDF]

, 2018
BackgroundMucosal melanoma is an aggressive melanoma with poor prognosis. We assessed efficacy of pembrolizumab in patients with advanced mucosal melanoma in KEYNOTE-001 (NCT01295827), -002 (NCT01704287), and -006 (NCT01866319).MethodsPatients received ...
Arance, Ana S, Brown, Ewan, Butler, Marcus, Daud, Adil, Ebbinghaus, Scot, Hamid, Omid, Hodi, F Stephen, Hoeller, Christoph, Ibrahim, Nageatte, Long, Jianmin, Mortier, Laurent, Ribas, Antoni, Robert, Caroline, Schachter, Jacob, Walpole, Euan   +14 more
core   +1 more source

Harnessing Next‐Generation 3D Cancer Models to Elucidate Tumor‐Microbiome Crosstalk

Advanced Healthcare Materials, EarlyView.
Centralizes the microbiome within 3D tumor‐microbiome model platforms, including spheroids, organoids, 3D‐bioprinted constructs, and microfluidic chips, each enabling structured host‐tumor‐microbe studies. These systems support bacterial colonization, facilitating investigation of microbial impacts on tumor growth, immunity, and therapy. The microbiome
Marina Green Buzhor, Giuseppe Longobardi, Or Kandli, Anne Krinsky, Opal Avramoff, Anshika Katyal, Koren Salomon, Adan Miari, Dana Venkert, Tania T. Barnatan, América García Alvarado, Shahar Greenberg, Ronit Satchi‐Fainaro   +12 more
wiley   +1 more source

Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study

Frontiers in Oncology, 2020
Background: The development of biomarkers predictive of response to immune checkpoint inhibitor (ICI) therapies in advanced melanoma is an area of great interest in oncology.
Muhammad A. Khattak, Muhammad A. Khattak, Muhammad A. Khattak, Afaf Abed, Afaf Abed, Anna L. Reid, Ashleigh C. McEvoy, Michael Millward, Michael Millward, Melanie Ziman, Elin S. Gray   +10 more
doaj   +1 more source

The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one [PDF]

, 2018
In renal cancer emerging treatment options are becoming available and there is a strong need to combine therapies to reformulate and adjourn clinical practice.
Botticelli, A., Marchetti, P., Nuti, M., Rughetti, A., Zizzari, I. G.   +4 more
core   +1 more source

Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.

Blood, 2023
The challenge of eradicating leukemia for patients with acute myelogenous leukemia (AML) following initial cytoreduction has motivated modern efforts to combine synergistic active modalities including immunotherapy.
L. Penter, Yang Liu, J. Wolff, Lin Yang, Len Taing, Aashna Jhaveri, Jackson Southard, Manishkumar Patel, Nicole Cullen, Kathleen L. Pfaff, Nicoletta Cieri, G. Oliveira, S. Kim-Schulze, S. Ranasinghe, Rebecca Leonard, T. Robertson, E. Morgan, Helen X. Chen, Minkyung H Song, M. Thurin, Shuqiang Li, S. Rodig, C. Cibulskis, S. Gabriel, P. Bachireddy, J. Ritz, H. Streicher, D. Neuberg, F. Hodi, S. Gnjatic, M. Davids, K. Livak, Jennifer Altreuter, F. Michor, R. Soiffer, Jacqueline S. Garcia, Catherine J. Wu   +36 more
semanticscholar   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review

Melanoma Management, 2018
Introduction: Immunotherapies, including checkpoint inhibitors (CIs) such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) inhibitors, are revolutionizing the treatment of advanced melanoma.
Elizabeth S Mearns, Jill A Bell, Aaron Galaznik, Stefanie M Puglielli, Allie B Cichewicz, Talia Boulanger, Ignacio Garcia-Ribas   +6 more
doaj   +1 more source

The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma [PDF]

, 2015
The melanoma-specific graded prognostic assessment (msGPA) assigns patients with brain metastases from malignant melanoma to 1 of 4 prognostic groups.
A Likhacheva, A Snyder, Adam Bloomfield, AM Broadbent, Andrew Furness, Anna Wilkins, C Nieder, C Nieder, D Mathieu, D Rades, E Weltman, FE Harrell Jr, GV Long, J Larkin, J Lorenzoni, J Raizer, James Larkin, JG Lorenzoni, K Margolin, Kevin Harrington, LE Gaspar, M Staudt, MA Hofmann, Nuria Porta, P Royston, PC Tumeh, PW Sperduto, PW Sperduto, R Dummer, R Fisher, R Partl, Richard W Corbett, SL Morris, Stephen Morris, T Serizawa, TK Eigentler, Zohra Ali   +36 more
core   +2 more sources